Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
PLoS Comput Biol ; 19(5): e1011124, 2023 05.
Article in English | MEDLINE | ID: mdl-37205708

ABSTRACT

Coronaviruses (CoVs) use -1 programmed ribosomal frameshifting stimulated by RNA pseudoknots in the viral genome to control expression of enzymes essential for replication, making CoV pseudoknots a promising target for anti-coronaviral drugs. Bats represent one of the largest reservoirs of CoVs and are the ultimate source of most CoVs infecting humans, including those causing SARS, MERS, and COVID-19. However, the structures of bat-CoV frameshift-stimulatory pseudoknots remain largely unexplored. Here we use a combination of blind structure prediction followed by all-atom molecular dynamics simulations to model the structures of eight pseudoknots that, together with the SARS-CoV-2 pseudoknot, are representative of the range of pseudoknot sequences in bat CoVs. We find that they all share some key qualitative features with the pseudoknot from SARS-CoV-2, notably the presence of conformers with two distinct fold topologies differing in whether or not the 5' end of the RNA is threaded through a junction, and similar conformations for stem 1. However, they differed in the number of helices present, with half sharing the 3-helix architecture of the SARS-CoV-2 pseudoknot but two containing 4 helices and two others only 2. These structure models should be helpful for future work studying bat-CoV pseudoknots as potential therapeutic targets.


Subject(s)
COVID-19 , Chiroptera , Humans , Animals , SARS-CoV-2/genetics , Frameshift Mutation , RNA , Nucleic Acid Conformation , RNA, Viral/genetics , RNA, Viral/chemistry
2.
Sci Data ; 10(1): 172, 2023 03 28.
Article in English | MEDLINE | ID: mdl-36977689

ABSTRACT

Crop type maps identify the spatial distribution of crop types and underpin a large range of agricultural monitoring applications ranging from early warning of crop shortfalls, crop condition assessments, production forecasts, and damage assessment from extreme weather, to agricultural statistics, agricultural insurance, and climate mitigation and adaptation decisions. Despite their importance, harmonized, up-to-date global crop type maps of the main food commodities do not exist to date. To address this critical data gap of global-scale consistent, up-to-date crop type maps, we harmonized 24 national and regional datasets from 21 sources covering 66 countries to develop a set of Best Available Crop Specific masks (BACS) over the major production and export countries for wheat, maize, rice, and soybeans, in the context of the G20 Global Agriculture Monitoring Program, GEOGLAM.

3.
Biomed Opt Express ; 12(9): 5812-5828, 2021 Sep 01.
Article in English | MEDLINE | ID: mdl-34692217

ABSTRACT

The biological effects of terahertz (THz) radiation have been observed across multiple levels of biological organization, however the sub-cellular mechanisms underlying the phenotypic changes remain to be elucidated. Filamentous protein complexes such as microtubules are essential cytoskeletal structures that regulate diverse biological functions, and these may be an important target for THz interactions underlying THz-induced effects observed at the cellular or tissue level. Here, we show disassembly of microtubules within minutes of exposure to extended trains of intense, picosecond-duration THz pulses. Further, the rate of disassembly depends on THz intensity and spectral content. As inhibition of microtubule dynamics is a mechanism of clinically-utilized anti-cancer agents, disruption of microtubule networks may indicate a potential therapeutic mechanism of intense THz pulses.

4.
3 Biotech ; 10(5): 212, 2020 May.
Article in English | MEDLINE | ID: mdl-32351870

ABSTRACT

A total of nine endolichenic fungi were isolated from the foliose lichen Parmotrema rampoddense (Nyl.) Hale. Of the nine endolichenic fungi, three taxa (Fusarium proliferatum, Nemania primolutea, Daldinia eschsholtzii) showed antibacterial activities as determined by the disk diffusion assay against ESKAPE bacterial pathogens. Fusarium proliferatum gave the most active fungal extract with zone of inhibition values of 15 mm and 19 mm against E. faecalis and S. aureus, respectively. Further chromatographic purification of the F. proliferatum ethyl acetate extract led to the isolation and identification of bis(2-ethylhexyl)terephthalate (1), acetyl tributyl citrate (2), and fusarubin (3). Acetyl tributyl citrate (2) exhibited moderate antibacterial activity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus.

5.
Article in English | MEDLINE | ID: mdl-32074218

ABSTRACT

Proinflammatory and inflammatory mediators induced by Trypanosoma cruzi infection increase the oxidative stress, generating toxicity for cells targeting mitochondria of different tissues. We studied the activity of citrate synthase and complexes I-IV of respiratory chain in mitochondria of blood lymphomonocyte fraction, from albino Swiss mice infected with different isolates of T. cruzi , during Chagas disease evolution. Complexes I-IV were modified in infected groups (p<0.05) in all the stages, and an inflammatory process of different magnitudes was detected in the heart and skeletal muscle according to the isolate. The citrate synthase activity presented modifications in the SGO Z12 and the Tulahuen group (p<0.05). Hearts showed fiber fragmentation and fibrosis; skeletal muscle presented inflammatory infiltrates and in the Tulahuen infected group, there were also amastigote nests. The inflammatory processes produced an oxidative stress that induced different alterations of mitochondrial enzymes activities in the lymphomonocyte fraction that can be detected by a simple blood extraction, suggesting that they could be used as disease markers, especially in the indeterminate phase of Chagas disease.


Subject(s)
Chagas Disease/enzymology , Citrate (si)-Synthase/metabolism , Electron Transport Complex IV/metabolism , Mitochondria/enzymology , Animals , Chagas Disease/metabolism , Chagas Disease/physiopathology , Disease Models, Animal , Disease Progression , Male , Mitochondria/parasitology , Mitochondria/pathology , Parasitemia
6.
Med Sci Monit ; 24: 4567-4571, 2018 Jul 02.
Article in English | MEDLINE | ID: mdl-29965956

ABSTRACT

Chagas disease, also known as American trypanosomiasis, is a chronic and systemic parasitic infection which has become a serious epidemiological problem not only in endemic regions (Latin America), but also in non-endemic ones like North America, Europe, and Oceania. Subjects with the indeterminate chagasic form (ICF), a chronic asymptomatic disease stage, are the main sources of non-vectorial dissemination through blood transfusion, organ transplantation, and congenital transmission. It has been suggested that 94% of urban infections can be explained by these subjects. Under this scenario, the availability of simple and effective screening methods for ICF detection becomes crucial for both prevention of disease propagation and detection of clinical stages. Recently, a new non-invasive method has been proposed for ICF detection. It is based on surface high-resolution ECG and it could be easily adopted and included in modern ECG devices, overcoming the limitations of serological-based tests. The proposed method shows accuracy for early ICF screening, thus improving prognosis by defining the clinical stages and allowing appropriate and effective treatment.


Subject(s)
Chagas Disease/diagnosis , Electrocardiography/methods , Chagas Disease/epidemiology , Early Diagnosis , Humans , Mass Screening/methods
7.
Arch. argent. pediatr ; 116(3): 468-470, jun. 2018. ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-950029

ABSTRACT

En los neonatos, la parálisis facial es muy infrecuente y, por lo general, diagnosticada al nacer. Se presenta el primer caso de parálisis facial neonatal con identificación del virus del herpes simple 1 en el líquido cefalorraquídeo. Un varón de 35 días de vida acudió a Urgencias por la desviación de la comisura bucal hacia la izquierda y la ausencia de cierre del ojo derecho, sin sintomatología infecciosa ni antecedentes relevantes. La exploración física fue compatible con parálisis facial periférica. Las exploraciones complementarias de urgencia (hemograma, bioquímica, coagulación y citoquímica de líquido cefalorraquídeo) fueron normales. Fue ingresado con prednisolona oral y aciclovir intravenoso. La resonancia magnética craneal fue normal. A las 48 horas, se recibió el resultado positivo de la reacción en cadena de la polimerasa para el virus del herpes simple 1 en el líquido cefalorraquídeo. Con evolución favorable, completó 7 días de prednisolona oral y fue dado de alta tras 21 días de aciclovir intravenoso, con exploración neurológica previa normal.


Neonatal facial palsy is very uncommon and is generally diagnosed at birth. We present the first published case of neonatal facial palsy with identification of herpes simplex virus 1 in cerebrospinal fluid. A 35-day-old male was presented at the Emergency Department with mouth deviation to the left and impossibility of full closure of the right eye. There were no symptoms of infection or relevant medical history. Physical examination was compatible with peripheral facial palsy. Studies performed at admission were normal (blood count, biochemical analysis and coagulation blood tests and cerebrospinal fluid analysis). The patient was admitted on oral prednisolone and intravenous aciclovir. Cranial magnetic resonance was normal. Polymerase chain reaction test for herpes simplex virus 1 in cerebrospinal fluid was reported positive after 48 hours of admission. Patient followed good evolution and received prednisolone for 7 days and acyclovir for 21 days. At discharge, neurological examination was normal.


Subject(s)
Humans , Male , Infant , Herpesvirus 1, Human/isolation & purification , Facial Paralysis/diagnosis , Herpes Simplex/diagnosis , Antiviral Agents/administration & dosage , Acyclovir/administration & dosage , Prednisolone/administration & dosage , Cerebrospinal Fluid/virology , Treatment Outcome , Facial Paralysis/drug therapy , Facial Paralysis/virology , Glucocorticoids/administration & dosage , Herpes Simplex/drug therapy
8.
Arch Argent Pediatr ; 116(3): e468-e470, 2018 06 01.
Article in Spanish | MEDLINE | ID: mdl-29756726

ABSTRACT

Neonatal facial palsy is very uncommon and is generally diagnosed at birth. We present the first published case of neonatal facial palsy with identification of herpes simplex virus 1 in cerebrospinal fluid. A 35-day-old male was presented at the Emergency Department with mouth deviation to the left and impossibility of full closure of the right eye. There were no symptoms of infection or relevant medical history. Physical examination was compatible with peripheral facial palsy. Studies performed at admission were normal (blood count, biochemical analysis and coagulation blood tests and cerebrospinal fluid analysis). The patient was admitted on oral prednisolone and intravenous aciclovir. Cranial magnetic resonance was normal. Polymerase chain reaction test for herpes simplex virus 1 in cerebrospinal fluid was reported positive after 48 hours of admission. Patient followed good evolution and received prednisolone for 7 days and acyclovir for 21 days. At discharge, neurological examination was normal.


En los neonatos, la parálisis facial es muy infrecuente y, por lo general, diagnosticada al nacer. Se presenta el primer caso de parálisis facial neonatal con identificación del virus del herpes simple 1 en el líquido cefalorraquídeo. Un varón de 35 días de vida acudió a Urgencias por la desviación de la comisura bucal hacia la izquierda y la ausencia de cierre del ojo derecho, sin sintomatología infecciosa ni antecedentes relevantes. La exploración física fue compatible con parálisis facial periférica. Las exploraciones complementarias de urgencia (hemograma, bioquímica, coagulación y citoquímica de líquido cefalorraquídeo) fueron normales. Fue ingresado con prednisolona oral y aciclovir intravenoso. La resonancia magnética craneal fue normal. A las 48 horas, se recibió el resultado positivo de la reacción en cadena de la polimerasa para el virus del herpes simple 1 en el líquido cefalorraquídeo. Con evolución favorable, completó 7 días de prednisolona oral y fue dado de alta tras 21 días de aciclovir intravenoso, con exploración neurológica previa normal.


Subject(s)
Facial Paralysis/diagnosis , Herpes Simplex/diagnosis , Herpesvirus 1, Human/isolation & purification , Acyclovir/administration & dosage , Antiviral Agents/administration & dosage , Cerebrospinal Fluid/virology , Facial Paralysis/drug therapy , Facial Paralysis/virology , Glucocorticoids/administration & dosage , Herpes Simplex/drug therapy , Humans , Infant , Male , Prednisolone/administration & dosage , Treatment Outcome
9.
Exp Parasitol ; 189: 19-27, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29726395

ABSTRACT

Combination therapies based on the available drugs have been proposed as promising therapeutic alternatives for many diseases. Clomipramine (CLO) has been found to modify the evolution of the experimental infection. The objective of this study was to evaluate the combined effect of benznidazole (BZ) and clomipramine (CLO) against different life-stages of Trypanosoma cruzi in vitro and their efficacy in a murine model. Life-stages of T. cruzi, BZ-partially-resistant (Y) strain, were incubated with BZ and CLO and isobolograms and combination index (CI) were obtained. Swiss mice were infected with trypomastigotes and different treatment schedules were performed, each of which consisted of 30 consecutive daily doses. Treatment efficacy was evaluated by comparing parasitemia, qPCR, survival and histological analysis. These results were analyzed using multivariate analysis to determine the combined effect of the drugs in vivo. CLO + BZ showed synergistic activity in vitro against the clinically relevant life-stages of T. cruzi. The most susceptible forms were the intracellular amastigotes (CI: 0.20), followed by trypomastigotes (CI: 0.60), with no toxicity upon mammalian cells. The combination of both drugs CLO (1.25 mg/kg) and BZ (6.25 mg/kg), in vivo, significantly diminished the parasitic load in blood and the mortality rate. CLO + BZ presented a similar inflammatory response in cardiac and skeletal muscle (amount of inflammatory cells) to BZ (6.25 mg/kg). Finally, the results from the principal component analysis reaffirmed that both drugs administered in combination presented higher activity compared with the individual administration in the acute experimental model.


Subject(s)
Chagas Disease/drug therapy , Clomipramine/pharmacology , Nitroimidazoles/pharmacology , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Animals , Clomipramine/therapeutic use , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Female , Inhibitory Concentration 50 , Male , Mice , Multivariate Analysis , Muscle, Skeletal/parasitology , Muscle, Skeletal/pathology , Myocardium/pathology , Nitroimidazoles/therapeutic use , Parasitemia/drug therapy , Principal Component Analysis , Real-Time Polymerase Chain Reaction , Trypanocidal Agents/therapeutic use
10.
Mol Biochem Parasitol ; 222: 29-33, 2018 06.
Article in English | MEDLINE | ID: mdl-29709547

ABSTRACT

In the present work, we evaluated the effect of mixed Trypanosoma cruzi infections, studying the biological distribution of the different parasites in blood, heart and skeletal muscle during the acute phase. Albino Swiss mice were infected with different parasite strain/isolates or with a combination of them. The parasites in the different tissues were typified through specific PCR, population variability was analyzed through RFLP studies and parasitological and histopathological parameters were evaluated. We found a predominance of TcII and TcVI in all tissues samples respect to TcV and different parasite populations were found in circulation and in the tissues from the same host. These results verify the distribution of parasites in host tissues from early stages of infection and show biological interactions among different genotypes and populations of T. cruzi.


Subject(s)
Chagas Disease/parasitology , Trypanosoma cruzi/physiology , Animals , Chagas Disease/blood , Chagas Disease/pathology , Female , Genotype , Heart/parasitology , Humans , Male , Mice , Muscle, Skeletal/parasitology , Muscle, Skeletal/pathology , Polymerase Chain Reaction , Tissue Distribution , Trypanosoma cruzi/genetics , Trypanosoma cruzi/growth & development
11.
Am J Reprod Immunol ; 80(1): e12852, 2018 07.
Article in English | MEDLINE | ID: mdl-29577492

ABSTRACT

PROBLEM: The innate immune response of the placenta may participate in the congenital transmission of Chagas disease through releasing reactive oxygen and nitrogen intermediates. METHOD OF STUDY: Placental explants were cultured with 1 × 106 and 1 × 105 trypomastigotes of Tulahuen and Lucky strains and controls without parasites, and with the addition of nitric oxide synthase inhibitor Nω-Nitro-l-arginine methyl ester (l-NAME) and N-acetyl cysteine (NAC) as the reactive oxygen species (ROS) scavenger. Detachment of the syncytiotrophoblast (STB) was examined by histological analysis, and the nitric oxide synthase, endothelial (eNOS), and nitrotyrosine expressions were analyzed by immunohistochemistry, as well as the human chorionic gonadotrophin (hCG) levels in the culture supernatant through ELISA assays. Parasite load with qPCR using Taqman primers was quantified. RESULTS: The higher number of T. cruzi (106 ) increased placental infection, eNOS expression, nitrosative stress, and STB detachment, with the placental barrier being injured by oxidative stress. CONCLUSION: The higher number of parasites caused deleterious consequences to the placental barrier, and the inhibitors (l-NAME and NAC) prevented the damage caused by trypomastigotes in placental villi but not that of the infection. Moreover, trophoblast eNOS played a key role in placental infection with the highest inoculum of Lucky, demonstrating the importance of the enzyme and nitrosative-oxidative stress in Chagas congenital transmission.


Subject(s)
Chagas Disease/metabolism , Chagas Disease/parasitology , Nitric Oxide Synthase Type III/metabolism , Nitrosative Stress/physiology , Oxidative Stress/physiology , Placenta/metabolism , Placenta/parasitology , Trypanosoma cruzi/pathogenicity , Animals , Chorionic Gonadotropin/metabolism , Female , Nitric Oxide Synthase/metabolism , Pregnancy , Reactive Oxygen Species/metabolism , Trophoblasts/metabolism , Tyrosine/analogs & derivatives , Tyrosine/metabolism
12.
Rev Fac Cien Med Univ Nac Cordoba ; 74(3): 231-238, 2017 09 08.
Article in Spanish | MEDLINE | ID: mdl-29890097

ABSTRACT

Background: Mitochondrial activity is essential for cardiac and skeletal muscle. The relationship between mitochondrial dysfunction and different cardiovascular conditions has been well described. Pharmacological treatment for heart failure involves different drugs as: angiotensin-converting enzyme inhibitors, B-adrenergic blockers, digitalis glycosides and diuretics. The clinical benefit from medication is clear, however, the role of this drugs in mitochondrial metabolisms is not well understood. Aim of the study: The objective of our study was to analyze structural and functional characteristics of cardiac and skeletal muscle mitochondria in mice treated with drugs normally used for heart failure and compare it to a control group. Methods: Twenty-five Albino Mice divided in five groups were treated with heart failure medication during 30 days (group I to IV). 30 days after treatment they were sacrificed, heart and skeletal muscle were analyzed and compared with a control group (V). Results: Enzymatic activity was slightly increased in groups treated with heart failure medication compared to control group (p>0.05). Mitochondrial morphology was significantly altered in groups treated compared to control group, in addition, mitochondrial area was significantly increased in the treated groups, in both cardiac and skeletal muscle. Conclusions: We concluded that heart failure medication could produce modifications in mitochondrial function; we believe that mitochondria maintains the enzymatic activity by increasing size and modifying morphology. Methods: Twenty-five Albino Mice divided in five groups were treated with heart failure medication during 30 days (group I to IV). 30 days after treatment they were sacrificed, heart and skeletal muscle were analyzed and compared with a control group (V). Results: Enzymatic activity was slightly increased in groups treated with heart failure medication compared to control group (p>0.05). Mitochondrial morphology was significantly altered in groups treated compared to control group, in addition, mitochondrial area was significantly increased in the treated groups, in both cardiac and skeletal muscle. Conclusions: We concluded that heart failure medication could produce modifications in mitochondrial function; we believe that mitochondria maintains the enzymatic activity by increasing size and modifying morphology. Results: Enzymatic activity was slightly increased in groups treated with heart failure medication compared to control group (p>0.05). Mitochondrial morphology was significantly altered in groups treated compared to control group, in addition, mitochondrial area was significantly increased in the treated groups, in both cardiac and skeletal muscle. Conclusions: We concluded that heart failure medication could produce modifications in mitochondrial function; we believe that mitochondria maintains the enzymatic activity by increasing size and modifying morphology. Conclusions: We concluded that heart failure medication could produce modifications in mitochondrial function; we believe that mitochondria maintains the enzymatic activity by increasing size and modifying morphology.


Introducción: la actividad mitocondrial es esencial para el músculo cardíaco y esquelético. La relación entre la disfunción mitocondrial y diferentes condiciones cardiovasculares ha sido bien descrita. El tratamiento farmacológico de la insuficiencia cardíaca implica diferentes medicamentos como: inhibidores de la enzima convertidora de la angiotensina, bloqueadores B-adrenérgicos, glucósidos digitálicos y diuréticos. Los beneficios clínicos del tratamiento son claros, sin embargo, el papel de estos fármacos en el metabolismo mitocondrial no esta bien establecido.Objetivo del estudio: El objetivo de nuestro estudio fue analizar las características estructurales y funcionales de las mitocondrias del músculo cardíaco y esquelético en ratones tratados con fármacos habitualmente utilizados para la insuficiencia cardíaca y compararlo con un grupo control.Métodos: Veinticinco ratones albinos divididos en cinco grupos fueron tratados con la medicación para insuficiencia cardíaca durante 30 días (grupo I a IV). 30 días después del tratamiento se sacrificaron, el corazón y el músculo esquelético se analizaron y se compararon con un grupo control (V).Resultados: La actividad enzimática se incrementó ligeramente en los grupos tratados con medicamentos insuficiencia cardiaca en comparación con el grupo control (p> 0,05). morfología mitocondrial se modificó significativamente en los grupos tratados en comparación con el grupo control, además, el área mitocondrial fue significativamente mayor en los grupos tratados, tanto en el músculo cardíaco y estriado.Conclusiones: Concluimos que la medicación insuficiencia cardíaca podría producir modificaciones en la función mitocondrial; creemos que las mitocondrias pueden mantener la actividad enzimática mediante el aumento de tamaño y modificación de la morfología. Objetivo: El objetivo de nuestro estudio fue analizar las características estructurales y funcionales de las mitocondrias del músculo cardíaco y esquelético en ratones tratados con fármacos habitualmente utilizados para la insuficiencia cardíaca y compararlo con un grupo control. Métodos: Veinticinco ratones albinos divididos en cinco grupos fueron tratados con la medicación para insuficiencia cardíaca durante 30 días (grupo I a IV). 30 días después del tratamiento se sacrificaron, el corazón y el músculo esquelético se analizaron y se compararon con un grupo control (V).Resultados: La actividad enzimática se incrementó ligeramente en los grupos tratados con medicamentos insuficiencia cardiaca en comparación con el grupo control (p> 0,05). morfología mitocondrial se modificó significativamente en los grupos tratados en comparación con el grupo control, además, el área mitocondrial fue significativamente mayor en los grupos tratados, tanto en el músculo cardíaco y estriado.Conclusiones: Concluimos que la medicación insuficiencia cardíaca podría producir modificaciones en la función mitocondrial; creemos que las mitocondrias pueden mantener la actividad enzimática mediante el aumento de tamaño y modificación de la morfología. Resultados: La actividad enzimática se incrementó ligeramente en los grupos tratados con medicamentos insuficiencia cardiaca en comparación con el grupo control (p> 0,05). morfología mitocondrial se modificó significativamente en los grupos tratados en comparación con el grupo control, además, el área mitocondrial fue significativamente mayor en los grupos tratados, tanto en el músculo cardíaco y estriado.Conclusiones: Concluimos que la medicación insuficiencia cardíaca podría producir modificaciones en la función mitocondrial; creemos que las mitocondrias pueden mantener la actividad enzimática mediante el aumento de tamaño y modificación de la morfología. Conclusiones: Concluimos que la medicación insuficiencia cardíaca podría producir modificaciones en la función mitocondrial; creemos que las mitocondrias pueden mantener la actividad enzimática mediante el aumento de tamaño y modificación de la morfología.


Subject(s)
Antihypertensive Agents/therapeutic use , Cardiotonic Agents/pharmacology , Diuretics/pharmacology , Heart Failure/drug therapy , Isosorbide Dinitrate/pharmacology , Mitochondria, Heart/drug effects , Animals , Antihypertensive Agents/pharmacology , Atenolol/pharmacology , Digoxin/pharmacology , Disease Models, Animal , Electrocardiography , Enalapril/pharmacology , Female , Furosemide/pharmacology , Heart Failure/physiopathology , Male , Mice , Mitochondria, Heart/physiology , Mitochondria, Heart/ultrastructure , Spironolactone/pharmacology
13.
Exp Mol Pathol ; 98(3): 467-75, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25835781

ABSTRACT

Trypanosoma cruzi invasion and replication in cardiomyocytes and other tissues induce cellular injuries and cytotoxic reactions, with the production of inflammatory cytokines and nitric oxide, both sources of reactive oxygen species. The myocyte response to oxidative stress involves the progression of cellular changes primarily targeting mitochondria. Similar alterations could be taking place in mitochondria from the skeletal muscle; if that is the case, a simple skeletal muscle biopsy would give information about the cardiac energetic production that could be used as a predictor of the chagasic cardiopathy evolution. Therefore, in the present paper we studied skeletal muscle mitochondrial structure and the enzymatic activity of citrate synthase and respiratory chain complexes I to IV (CI-CIV), in Albino Swiss mice infected with T. cruzi, Tulahuen strain and SGO Z12 and Lucky isolates, along the infection. Changes in the mitochondrial structure were detected in 100% of the mitochondria analyzed from the infected groups: they all presented at least 1 significant abnormality such as increase in their matrix or disorganization of their cristae, which are probably related to the enzymatic dysfunction. When we studied the Krebs cycle functionality through the measurement of the specific citrate synthase activity, we found it to be significantly diminished during the acute phase of the infection in Tulahuen and SGO Z12 infected groups with respect to the control one; citrate synthase activity from the Lucky group was significantly increased (p<0.05). The activity of this enzyme was reduced in all the infected groups during the chronic asymptomatic phase (p<0.001) and return to normal values (Tulahuen and SGO Z12) or increased its activity (Lucky) by day 365 post-infection (p.i.). When the mitochondrial respiratory chain was analyzed from the acute to the chronic phase of the infection through the measurement of the activity of complexes I to IV, the activity of CI remained similar to control in Tulahuen and Lucky groups, but was significantly augmented in the SGO Z12 one in the acute and chronic phases (p<0.05). CII increased its activity in Tulahuen and Lucky groups by day 75 p.i. and in SGO Z12 by day 365 p.i. (p<0.05). CIII showed a similar behavior in the 3 infected groups, remaining similar to control values in the first two stages of the infection and significantly increasing later on (p<0.0001). CIV showed an increase in its activity in Lucky throughout all stages of infection (p<0.0001) and an increase in Tulahuen by day 365days p.i. (p<0.0001); SGO Z12 on the other hand, showed a decreased CIV activity at the same time. The structural changes in skeletal muscle mitochondria and their altered enzyme activity began in the acute phase of infection, probably modifying the ability of mitochondria to generate energy; these changes were not compensated in the rest of the phases of the infection. Chagas is a systemic disease, which produces not only heart damage but also permanent skeletal muscle alterations.


Subject(s)
Chagas Disease/metabolism , Mitochondria, Muscle/metabolism , Muscle, Skeletal/metabolism , Animals , Chagas Disease/pathology , Electron Transport Chain Complex Proteins/metabolism , Female , Male , Mice , Mitochondria, Muscle/ultrastructure , Muscle, Skeletal/ultrastructure
14.
Acta Trop ; 145: 79-87, 2015 May.
Article in English | MEDLINE | ID: mdl-25733492

ABSTRACT

Thioridazine (TDZ) is a phenothiazine that has been shown to be one of the most potent phenothiazines to inhibit trypanothione reductase irreversibly. Trypanothione reductase is an essential enzyme for the survival of Trypanosoma cruzi in the host. Here, we reviewed the use of this drug for the treatment of T. cruzi experimental infection. In our laboratory, we have studied the effect of TDZ for the treatment of mice infected with different strains of T. cruzi and treated in the acute or in the chronic phases of the experimental infection, using two different schedules: TDZ at a dose of 80 mg/kg/day, for 3 days starting 1h after infection (acute phase), or TDZ 80 mg/kg/day for 12 days starting 180 days post infection (d.p.i.) (chronic phase). In our experience, the treatment of infected mice, in the acute or in the chronic phases of the infection, with TDZ led to a large reduction in the mortality rates and in the cardiac histological and electrocardiographical abnormalities, and modified the natural evolution of the experimental infection. These analyses reinforce the importance of treatment in the chronic phase to decrease, retard or stop the evolution to chagasic myocardiopathy. Other evidence leading to the use of this drug as a potential chemotherapeutic agent for Chagas disease treatment is also revised.


Subject(s)
Chagas Disease/drug therapy , Enzyme Inhibitors/pharmacology , NADH, NADPH Oxidoreductases/antagonists & inhibitors , Thioridazine/pharmacology , Animals , Dose-Response Relationship, Drug , Mice , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology
16.
Arch Med Res ; 45(3): 237-46, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24657595

ABSTRACT

BACKGROUND AND AIMS: The fundamental mechanisms involved in the genesis and progression of heart failure are not clearly understood. The present study was conducted to analyze the cardiac mitochondrial involvement in heart failure, the possible parallelism between cardiac and skeletal muscle and if there is a link between clinical symptoms and mitochondrial damage. METHODS: Left ventricle and pectoral biopsies were obtained from patients with heart failure (n: 21) and patients with inter-auricular communication as the unique diagnosis for surgery (n: 6). Mitochondria were isolated from these tissues and studied through electron microscopy, spectrophotometry to measure the activity of respiratory complex III and immunohistochemistry to determine the presence of reactive oxygen species. RESULTS: More than 90% of cardiac and skeletal muscle mitochondria presented structural and functional alterations in relation to an increment in the reactive oxygen species production, even in patients without the presence of any clinical Framingham criteria. CONCLUSIONS: We demonstrated some parallelism between cardiac and skeletal muscle mitochondrial alterations in patients with heart failure and that these alterations begin before the major clinical Framingham criteria are installed, pointing to mitochondria as one of the possibly responsible factors for the evolution of cardiac disease.


Subject(s)
Heart Failure/metabolism , Heart Failure/pathology , Mitochondria, Muscle/metabolism , Mitochondria, Muscle/pathology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Myocardium/metabolism , Myocardium/pathology , Aged , Case-Control Studies , Female , Humans , Male , Middle Aged , Mitochondria, Muscle/ultrastructure , Muscle, Skeletal/ultrastructure , Myocardium/ultrastructure , Reactive Oxygen Species/metabolism
17.
Acta Trop ; 133: 98-109, 2014 May.
Article in English | MEDLINE | ID: mdl-24560963

ABSTRACT

We evaluated the presence and distribution of two Trypanosoma cruzi natural isolates in blood, heart, skeletal muscle, liver, and spleen tissues in the acute phase of the experimental infection (35 days postinfection) in order to determine if the populations present in blood were different to those found in the tissues of the same host. Thirty mice were infected with 50 forms of each isolate or with a combination of them. Presence and molecular characterization of the parasites in the host tissues were determined by specific PCR. Cardiac and skeletal muscle alterations were analyzed by histological studies. T. cruzi variability in the host tissues was analyzed through RFLP studies. Both isolates used consisted of a mixture of two T. cruzi lineages. Specific PCRs were positive for most of the samples from the 3 groups analyzed. Cardiac and skeletal muscle sections from the groups infected with one isolate presented mild to moderate inflammatory infiltrates; the group infected with both isolates showed severe inflammatory infiltrates and the presence of amastigote nests in both tissues. Different parasite populations were found in circulation and in the tissues from the same host. These results are important for patients with high probability of mixed infections in endemic areas and contribute to the knowledge of parasite/host interactions.


Subject(s)
Blood/parasitology , Chagas Disease/parasitology , Genetic Variation , Trypanosoma cruzi/classification , Trypanosoma cruzi/isolation & purification , Animals , Chagas Disease/pathology , DNA, Protozoan/genetics , Disease Models, Animal , Female , Genotype , Male , Mice , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Trypanosoma cruzi/genetics
19.
Gac. sanit. (Barc., Ed. impr.) ; 27(3): 258-262, mayo-jun. 2013. tab
Article in Spanish | IBECS | ID: ibc-114594

ABSTRACT

Objetivo: Describir la variabilidad entre niveles hospitalarios del porcentaje de cesáreas y los motivos para realizarlas en mujeres sin y con cesárea previa. Métodos: Estudio transversal descriptivo de la actividad obstétrica de 111 hospitales (año 2010) clasificados en seis niveles. Se crearon 10 grupos de motivos de cesárea partiendo del diagnóstico principal. Se calcularon medidas descriptivas de tendencia central y de dispersión, y se utilizó el test de Kruskall-Wallis para la comparación entre niveles. Resultados: El porcentaje global de cesáreas fue del 25,4%. Los hospitales privados y públicos de menor nivel tecnológico presentaron mayores porcentajes de cesáreas en mujeres sin cesárea previa (34,7% y 30,4% en los privados y 22,4% en los públicos de menor nivel). Entre los niveles públicos no hubo diferencias en el porcentaje de cesáreas indicadas. Conclusiones: Investigaciones sobre factores no clínicos podrían aclarar las diferencias en los porcentajes de cesáreas entre los hospitales privados y los públicos, y entre los niveles de los públicos (AU)


Objective: To describe variability in the cesarean ratio and indications for this procedure in women with and without a previous cesarean section. Methods: We conducted a cross-sectional study of 111 hospitals (year 2010) categorized in six levels. Ten groups of indications for cesarean section were developed. Measures of central tendency and diversity were used to determine variability and the Kruskal-Wallis test was used for comparisons among hospital levels. Results: The percentage of cesarean sections was 25.4%. In women without a previous cesarean section, the percentage was higher in private and public hospitals with a lower technological level (34.7% and 30.4% in private and 22.4% in lower level public hospitals). Among public hospital levels, no differences in the percentage of cesarean sections indicated were observed. Conclusions: Research on non-clinical factors could clarify the differences in the ratio of cesarean sections in private hospitals compared with public hospitals and among distinct levels of public hospitals (AU)


Subject(s)
Humans , Female , Pregnancy , Cesarean Section/statistics & numerical data , Hospitals, Maternity/statistics & numerical data , Obstetric Labor Complications/epidemiology , Public Sector/statistics & numerical data , Private Sector/statistics & numerical data , Risk Factors
20.
Parasitol Int ; 62(3): 293-9, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23500720

ABSTRACT

Alternative strategies are being designed to identify candidates among drugs already available on the market that could be used in combination to improve the efficacy of Chagas disease treatment. This work evaluates the effect of the association of clomipramine (CLO) with benznidazole (BZN) for the treatment of experimental Chagas disease in the acute stage, in Swiss albino mice infected with Trypanosoma cruzi Tulahuen strain. Infected mice were treated with CLO 5mg/kg/day and BZN 50 and 100mg/kg/day, each separately or together. Efficacy of the treatment was evaluated through parasitemia, survival, electrocardiography, histopathological studies, serological and PCR assays at 90 days post-infection (dpi). All treatments significantly (P<0.05) reduced mortality and decreased parasitemia. Histopathological analysis of liver and kidneys of mice treated with CLO and the drug combination showed less injury than mice treated only with BZN. The lower dose of BZN (50mg/kg/day) combined with CLO showed the same efficacy as the habitual dose of BZN (100mg/kg/day) combined with CLO. The therapeutic results from the combination of BZN with CLO presented lesser side effects than the treatment with BZN.


Subject(s)
Chagas Disease/drug therapy , Clomipramine/therapeutic use , Nitroimidazoles/therapeutic use , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi/drug effects , Animals , Chagas Disease/pathology , Clomipramine/pharmacology , Disease Models, Animal , Drug Evaluation, Preclinical , Electrocardiography , Female , Intestines/pathology , Kidney/pathology , Liver/pathology , Male , Mice , Muscle, Skeletal/pathology , Myocardium/pathology , Nitroimidazoles/pharmacology , Parasitemia , Trypanocidal Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...